
Research ReportKRYS
Krystal Biotech (KRYS): VYJUVEK Growth Funds Pipeline
Krystal Biotech pairs a profitable commercial launch with a deep gene-therapy pipeline, but valuation leaves less room for execution missteps. VYJUVEK is driving strong revenue growth while multiple programs advance toward key clinical milestones.
Nov 2, 202621 MIN
